NEMOTORNYE SIMPTOMY TsERVIKAL'NOY DISTONII


Cite item

Full Text

Abstract

About the authors

T Yu Avseytseva

3 ЦВКГ им. А.А. Вишневского

г. Красногорск

A F Ivolgin

3 ЦВКГ им. А.А. Вишневского

г. Красногорск

References

  1. Jankovic J, Treatment of dystonia, Lancet Neurol, 2006;5:864-72.
  2. Chan J, Idiopathic cervical dystonia: clinical characteristics, / Chan J, Brin MF, Fahn S, // Mov Disord, 1991;6:119-26.
  3. Epidemiologic Study of Dystonia in Europe (ESDE) Collaborative Group, A prevalence study of primary dystonia in eight European countries, J Neurol, 2000;247:787-92.
  4. Jahanshahi M, Factors that ameliorate or aggravate spasmodic torticollis, J Neurol Neurosurg Psychiatry, 2000;68:227-9.
  5. Marie-Helene Marion, British Neurotoxin Network recommendations for managing cervical dystonia in patients with a poor re- sponse to botulinum toxin / Marie-Helene Marion, Miles Humberstone, Richard Grunewald, Sunil Wimalaratna
  6. H. A. Jinnah, for the Dystonia Coalition Investigators: Longitudinal Studies of Botulinum Toxin in Cervical Dystonia: Why Do Patients Discontinue Therapy? / H. A. Jinnah, Cynthia L Comella, Joel Perlmutter, Codrin Lungu, Mark Hallett // Toxicon. 2018 Jun 1; 147: 89-95.
  7. Miguel Coelho, Pain and Quality of Life in the Treatment of Cervical Dystonia / Miguel Coelho, Anabela Ferreira Valadas, Tiago Mestre, Joaquim J Ferreira
  8. Kutvonen O, Pain in spasmodic torticollis / Kutvonen O, Dastidar P, Nurmikko T // Pain, 1997;69:279-86.
  9. Lobbezoo F, Pain perception in idiopathic cervical dystonia (spasmodic torticollis) / Lobbezoo F, Tanguay R, Thon MT, Lavigne GJ // Pain, 1996;67:483-91.
  10. Konrad C, Orthopedic and neurological complications of cervical dystonia - review of the literature / Konrad C, Vollmer-Haase J, Anneken K, Knecht S // Acta Neurol Scand, 2004;109:369-73.
  11. Tonomura Y, Atlantoaxial rotatory subluxation associated with cervical dystonia / Tonomura Y, Kataoka H, Sugie K, et al. // Spine (Phila Pa 1976), 2007;32:E561-4.
  12. Camfield L, Impact of cervical dystonia on quality of life / Camfield L, Ben-Shlomo Y, Warner TT // Mov Disord, 2002;17:838-41.
  13. Hilker R, Health related quality of life is improved by botulinum neurotoxin type A in long term treated patients with focal dystonia / Hilker R, Schischniaschvili M, Ghaemi M, et al. // J Neurol Neurosurg Psychiatry, 2001;71:193-9.
  14. Skogseid IM, Determinants and status of quality of life after long-term botulinum toxin therapy for cervical dystonia / Skogseid IM, Malt UF, Roislien J, Kerty E // Eur J Neurol, 2007;14: 1129-37.
  15. Cano SJ, Capturing the true burden of dystonia on patients: the Cervical Dystonia Impact Profile (CDIP-58) / Cano SJ, Warner TT, Linacre JM, et al. // Neurology, 2004;63:1629-33.
  16. Simpson DM, Assessment: Botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology / Simpson DM, Blitzer A, Brashear A, et al. // Neurology, 2008;70:1699-1706.
  17. орлова о.Р. опыт применения нового ботулинического токсина типа А Релатокс в клинической практике / орлова о.Р., Коновалова З.Н., Мингазова Л.Р., Саксонова е.В., Сойхер М.И., Щелокова е.Б. // Вестник МооСБт. Метаморфозы. 2014; 8 (но- ябрь): 2-4.
  18. Латышева Н.В. Головная боль в практике врача-косметолога / Латышева Н.В., орлова о.Р. // Вестник МооСБт. Метамор- фозы. 2017; 18: 81-86.

Copyright (c) 2018 Avseytseva T.Y., Ivolgin A.F.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies